VectorY is participating in a large cureQ consortium named “Predict, Delay & Cure polyglutamine(Q) caused neurodegeneration”.
VectorY is participating in a large cureQ consortium named “Predict, Delay & Cure polyglutamine(Q) caused neurodegeneration”. The consortium is funded by a 4,7 million euro grant by the Dutch NWA-ORC 2021/2021 Impact Plan Approach and is a collaborative effort between biotech, academic groups and patient organizations on Huntington’s Disease and other polyQ disease. The consortium will collaborate to define the optimal moment to start treatment, targeting intermediate and early-onset forms of polyQ disorders, and improved disease models. Combining data from patient-derived cells and known clinical data as well as models for early-onset will be essential for various therapeutic strategies currently in pre-clinical stages. The complementary expertise of the different consortium members covers the entire trajectory from drug discovery to clinical trials.
